Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

A new DNA gyrase inhibitor subclass of the cyclothialidine family based on a bicyclic dilactam-lactone scaffold. Synthesis and antibacterial properties.

Angehrn P, Goetschi E, Gmuender H, Hebeisen P, Hennig M, Kuhn B, Luebbers T, Reindl P, Ricklin F, Schmitt-Hoffmann A.

J Med Chem. 2011 Apr 14;54(7):2207-24. doi: 10.1021/jm1014023. Epub 2011 Mar 9.

PMID:
21388139
2.

Design, synthesis, and structure-activity relationship studies of new phenolic DNA gyrase inhibitors.

Lübbers T, Angehrn P, Gmünder H, Herzig S.

Bioorg Med Chem Lett. 2007 Aug 15;17(16):4708-14. Epub 2006 Dec 22.

PMID:
17632001
3.

Novel ketolide antibiotics with a fused five-membered lactone ring--synthesis, physicochemical and antimicrobial properties.

Hunziker D, Wyss PC, Angehrn P, Mueller A, Marty HP, Halm R, Kellenberger L, Bitsch V, Biringer G, Arnold W, Stämpfli A, Schmitt-Hoffmann A, Cousot D.

Bioorg Med Chem. 2004 Jul 1;12(13):3503-19.

PMID:
15186835
4.

New antibacterial agents derived from the DNA gyrase inhibitor cyclothialidine.

Angehrn P, Buchmann S, Funk C, Goetschi E, Gmuender H, Hebeisen P, Kostrewa D, Link H, Luebbers T, Masciadri R, Nielsen J, Reindl P, Ricklin F, Schmitt-Hoffmann A, Theil FP.

J Med Chem. 2004 Mar 11;47(6):1487-513.

PMID:
14998336
5.

New anti-MRSA and anti-VRE carbapenems; synthesis and structure-activity relationships of 1beta-methyl-2-(thiazol-2-ylthio)carbapenems.

Sunagawa M, Itoh M, Kubota K, Sasaki A, Ueda Y, Angehrn P, Bourson A, Goetschi E, Hebeisen P, Then RL.

J Antibiot (Tokyo). 2002 Aug;55(8):722-57.

6.

In vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci.

Hebeisen P, Heinze-Krauss I, Angehrn P, Hohl P, Page MG, Then RL.

Antimicrob Agents Chemother. 2001 Mar;45(3):825-36.

7.

Design, synthesis, and structure-activity relationship studies of ATP analogues as DNA gyrase inhibitors.

Lübbers T, Angehrn P, Gmünder H, Herzig S, Kulhanek J.

Bioorg Med Chem Lett. 2000 Apr 17;10(8):821-6.

PMID:
10782694
8.

Structure-based design of beta-lactamase inhibitors. 2. Synthesis and evaluation of bridged sulfactams and oxamazins.

Hubschwerlen C, Angehrn P, Gubernator K, Page MG, Specklin JL.

J Med Chem. 1998 Oct 8;41(21):3972-5.

PMID:
9767634
9.

Structure-based design of beta-lactamase inhibitors. 1. Synthesis and evaluation of bridged monobactams.

Heinze-Krauss I, Angehrn P, Charnas RL, Gubernator K, Gutknecht EM, Hubschwerlen C, Kania M, Oefner C, Page MG, Sogabe S, Specklin JL, Winkler F.

J Med Chem. 1998 Oct 8;41(21):3961-71.

PMID:
9767633
10.

Design, synthesis, and evaluation of 2 beta-alkenyl penam sulfone acids as inhibitors of beta-lactamases.

Richter HG, Angehrn P, Hubschwerlen C, Kania M, Page MG, Specklin JL, Winkler FK.

J Med Chem. 1996 Sep 13;39(19):3712-22.

PMID:
8809160
11.

Antibacterial activities of epiroprim, a new dihydrofolate reductase inhibitor, alone and in combination with dapsone.

Locher HH, Schlunegger H, Hartman PG, Angehrn P, Then RL.

Antimicrob Agents Chemother. 1996 Jun;40(6):1376-81.

12.

Synthesis and structure-activity relationship of (lactamylvinyl)cephalosporins exhibiting activity against staphylococci, pneumococci, and enterococci.

Heinze-Krauss I, Angehrn P, Guerry P, Hebeisen P, Hubschwerlen C, Kompis I, Page MG, Richter HG, Runtz V, Stalder H, Weiss U, Wei CC.

J Med Chem. 1996 Apr 26;39(9):1864-71.

PMID:
8627610
13.

GyrB mutations in Staphylococcus aureus strains resistant to cyclothialidine, coumermycin, and novobiocin.

Stieger M, Angehrn P, Wohlgensinger B, Gmünder H.

Antimicrob Agents Chemother. 1996 Apr;40(4):1060-2.

14.

Cyclothialidine and its congeners: a new class of DNA gyrase inhibitors.

Goetschi E, Angehrn P, Gmuender H, Hebeisen P, Link H, Masciadri R, Nielsen J.

Pharmacol Ther. 1993 Nov;60(2):367-80. Review.

PMID:
8022866
15.

(6R)-6-(substituted methyl)penicillanic acid sulfones: new potent beta-lactamase inhibitors.

Adam S, Then R, Angehrn P.

J Antibiot (Tokyo). 1993 Apr;46(4):641-6.

16.

Antibacterial properties of Ro 40-6890, a broad-spectrum cephalosporin, and its novel orally absorbable ester, Ro 41-3399.

Angehrn P, Hohl P, Hubschwerlen C, Page M, Then R.

Antimicrob Agents Chemother. 1992 Dec;36(12):2825-34.

17.

Orally active 2-(alkyloxycarbonyl)-2-alkylideneethyl esters of cephalosporins.

Hubschwerlen C, Charnas R, Angehrn P, Furlenmeier A, Graser T, Montavon M.

J Antibiot (Tokyo). 1992 Aug;45(8):1358-64.

18.

Pyrimido[1,6-a]benzimidazoles: a new class of DNA gyrase inhibitors.

Hubschwerlen C, Pflieger P, Specklin JL, Gubernator K, Gmünder H, Angehrn P, Kompis I.

J Med Chem. 1992 Apr 17;35(8):1385-92.

PMID:
1315393
19.

Methylene (2S,5R)-6-(3-formylallylidene)penicillanate pivalate, a prodrug of a new beta-lactamase inhibitor.

Adam S, Then R, Angehrn P.

J Antibiot (Tokyo). 1992 Apr;45(4):587-8. No abstract available.

20.

In vitro and in vivo evaluation of Ro 09-1428, a new parenteral cephalosporin with high antipseudomonal activity.

Arisawa M, Sekine Y, Shimizu S, Takano H, Angehrn P, Then RL.

Antimicrob Agents Chemother. 1991 Apr;35(4):653-9.

21.
22.

Monocyclic and tricyclic analogs of quinolones: mechanism of action.

Georgopapadakou NH, Dix BA, Angehrn P, Wick A, Olson GL.

Antimicrob Agents Chemother. 1987 Apr;31(4):614-6.

23.

6-(E)-acetylmethylenepenicillanic acid, a potent beta-lactamase inhibitor.

Adam S, Then RL, Angehrn P.

J Antibiot (Tokyo). 1987 Jan;40(1):108-9. No abstract available.

24.

Multiply resistant mutants of Enterobacter cloacae selected by beta-lactam antibiotics.

Then RL, Angehrn P.

Antimicrob Agents Chemother. 1986 Nov;30(5):684-8.

25.

Potential prodrugs of 6-acetylmethylenepenicillanic acid (Ro 15-1903).

Adam S, Then R, Angehrn P.

J Antibiot (Tokyo). 1986 Jun;39(6):833-8.

26.
27.
29.

Synergistic antibacterial activity between L-norvalyl-L-1-aminoethylphosphonic acid and nocardicin A.

Angehrn P, Hall MJ, Lloyd WJ, Westmacott D.

Antimicrob Agents Chemother. 1984 May;25(5):607-11.

30.
31.

Cephalosporin resistance in strains of Klebsiella oxytoca isolated during antibiotic therapy.

Then RL, Glauser MP, Angehrn P, Arisawa M.

Zentralbl Bakteriol Mikrobiol Hyg A. 1983 Jul;254(4):469-79.

PMID:
6609500
32.
34.

New analogs of trimethoprim.

Then RL, Böhni E, Angehrn P, Plozza-Nottebrock H, Stoeckel K.

Rev Infect Dis. 1982 Mar-Apr;4(2):372-7. Review.

PMID:
7051237
35.

Antibacterial properties of Ro 13-99041, a long-acting new cephalosporin.

Angehrn P, Probst PJ.

Chemotherapy. 1981;27 Suppl 1:9-14.

PMID:
7249797
36.

Ro 13-9904, a long-acting broad-spectrum cephalosporin: in vitro and in vivo studies.

Angehrn P, Probst PJ, Reiner R, Then RL.

Antimicrob Agents Chemother. 1980 Dec;18(6):913-21.

37.

Ro 13-9904/001, a novel potent and long-acting parenteral cephalosporin.

Reiner R, Weiss U, Brombacher U, Lanz P, Montavon M, Furlenmeier A, Angehrn P, Probst PJ.

J Antibiot (Tokyo). 1980 Jul;33(7):783-6.

38.
39.

[Fundamentals of the chemotherapy of trichomoniasis and amebiasis with ornidazole].

Richle R, Scholer HJ, Angehrn P, Fernex M, Hummler H, Jeunet F, Schärer K, Schüpbach K, Schwartz DE.

Arzneimittelforschung. 1978;28(4):612-25. German. No abstract available.

PMID:
581938
41.
42.

Letter: Co-trimoxazole resistance.

Then R, Angehrn P.

Br Med J. 1974 Jan 12;1(5897):78-9. No abstract available.

43.

Nature of the bacterial action of sulfonamides and trimethoprim, alone and in combination.

Then R, Angehrn P.

J Infect Dis. 1973 Nov;128:Suppl:498-501. No abstract available.

PMID:
4585954
44.

Sulphonamide-induced 'thymineless death' in Escherichia coli.

Then R, Angehrn P.

J Gen Microbiol. 1973 Jun;76(2):255-63. No abstract available.

PMID:
4579126
45.

Effects of trimethoprim on Escherichia coli under limited nutrition.

Then R, Angehrn P.

Arzneimittelforschung. 1973 Mar;23(3):451-5. No abstract available.

PMID:
4575178
46.

Nature of trimethoprim-induced death in Escherichia coli.

Angehrn P, Then R.

Arzneimittelforschung. 1973 Mar;23(3):447-51. No abstract available.

PMID:
4575177
47.

Investigations on the mode of action of the combination sulfamethoxazole-trimethoprim.

Angehrn P, Then R.

Chemotherapy. 1973;19(1):1-10. No abstract available.

PMID:
4583774
48.

Effects of trimethoprim and its antagonists on RNA synthesis in Escherichia coli.

Then R, Angehrn P.

Biochim Biophys Acta. 1972 Nov 16;287(1):98-105. No abstract available.

PMID:
4569161
49.

[Effects of trimethoprim and its antagonists on RNA synthesis in Escherichia coli].

Then R, Angehrn P.

Hoppe Seylers Z Physiol Chem. 1972 May;353(5):762. German. No abstract available.

PMID:
4560667
50.

[The inactiviation of thiocarlide by culture media components].

Angehrn P, Gubler HU.

Schweiz Med Wochenschr. 1967 Aug 5;97(31):1022-3. German. No abstract available.

PMID:
4174228

Supplemental Content

Loading ...
Support Center